Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

Drawing inferences from observational data with possible confounding Heart failure is increasing in prevalence and is a major cause of morbidity and mortality worldwide,1 with prevalence ranging from ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

Inspra (eplerenone tablets; Pfizer, Inc., New York, NY) is an aldosterone blocker that works by binding at the mineralocorticoid receptor. It has some similarities to the potassium-sparing ...

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

AR = Androgen receptor; ER = Estrogen receptor; GR = Glucocorticoid receptor; MR = Mineralocorticoid receptor; PR = Progesterone receptor. The relative binding affinity (%) of the main progestins ...

Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Serum uric acid (SUA), a product of ...

The orally-active drug, a non-steroidal mineralocorticoid receptor antagonist (nsMRA), is currently in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension – in other words ...

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented ...